1. Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis.
- Author
-
Benoit JM, Breznik JA, Huynh A, Cowbrough B, Baker B, Heessels L, Lodhi S, Yan E, Bhakta H, Clare R, Nazy I, Bramson JL, Larché MJ, and Bowdish DM
- Subjects
- Humans, Middle Aged, Female, Male, Aged, Adult, Spike Glycoprotein, Coronavirus immunology, Immunoglobulin G blood, Immunoglobulin G immunology, BNT162 Vaccine immunology, Immunoglobulin A blood, Immunoglobulin A immunology, CD8-Positive T-Lymphocytes immunology, Immunogenicity, Vaccine, Scleroderma, Systemic immunology, SARS-CoV-2 immunology, Immunity, Humoral, COVID-19 immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Immunity, Cellular, Antibodies, Viral blood, Antibodies, Viral immunology, Vaccination
- Abstract
Individuals with systemic sclerosis (SSc) are particularly susceptible to SARS-CoV-2 infections, yet it remains to be determined if they generate humoral and cellular responses comparable to controls following SARS-CoV-2 vaccinations. Herein, we collected blood and serum after second, third, and fourth SARS-CoV-2 vaccinations in patients with SSc and controls. Following each dose, participants with SSc mounted comparable serum anti-RBD IgG, anti-RBD IgA, and spike-specific CD4
+ and CD8+ T cell responses to those found in controls. At 3 months post dose 2, the frequencies of Th1, Th2, Th17, and Treg spike-specific CD4+ T cells in participants with SSc did not differ from controls. At 2-6 weeks post dose 3, participants with SSc displayed reduced frequencies, but not numbers, of Th17-polarized spike-specific CD4+ T cells. Thus, participants with SSc did not display significantly weaker humoral or cellular responses to SARS-CoV-2 vaccination than controls, enabling reassurance of vaccine immunogenicity in participants with SSc., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Maggie J. Larche reports financial support was provided by Scleroderma Canada. DMEB has received honorarium for consulting on the topic of vaccines from Pfizer-Canada and AstraZeneca. MJL is on the Advisory Boards/Speakers Bureaus for AbbVie, Actelion, Amgen, Astra-Zeneca, Boehringer-Ingelheim, BMS, Fresenius-Kabi, Gilead, GSK, Lilly, Mallinckrodt, Novartis, Pfizer, Sanofi, SOBI, UCB, and Scleroderma Society of Ontario/Canada. None of the other authors have competing interests., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF